1.Arthritis Res Ther. 2006;8(3):R80.
2.Epub 2006 Apr 28. Obesity (Silver Spring). 2010 Nov;18(11):2234-6.
3.Epub 2010 Mar 18. J Immunol. 2011 Feb 15;186(4):2613-22.
4.J Invest Dermatol. 2011 Dec;131(12):2428-37. Epub 2011 Sep 1.
Interleukin-36 is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36βactivates NF-kappa-B and MAPK signaling pathways in target cells linked to a pro-inflammatory response. IL-36βare involved in a number of fundamental biological processes such as stimulating production of interleukin-6 and interleukin-8 in synovial fibrobasts, articular chondrocytes and mature adipocytes, inducing expression of a number of antimicrobial peptides including beta-defensin 4 and beta-defensin 103 as well as a number of matrix metalloproteases , inducing the production of proinflammatory cytokines in bone marrow-derived dendritic cells (BMDCs), including IL-12, Il-1 beta, IL-6, TNF-alpha and IL-23, and activating p38 MAPK phosphorylation in BMDCs.
Measured by its ability to induce IL-8 secretion in A431 human epithelial carcinoma cells. The ED50 for this effect is less than 10ng/ml.
1μg (R: reducing condition, N: non-reducing condition).